stockrowAgilent Technologies, Inc.
A Healthcare Diagnostics & Research
Agilent Technologies, Inc.’s revenue for fiscal 2025 (year ended October 2025) was $6.9 billion, up 6.73% from fiscal 2024.
- Revenue
- +8.06%
- EPS
- +8.47%
- Free cash flow
- +69.5%
- Total debt
- +8.81%
Quarter to July 2026, against a year earlier
Follow A
Alert me
Agilent Technologies, Inc. (A) Return on invested capital
Agilent Technologies, Inc.'s return on invested capital over the twelve months to 31 July 2026 was 11.1%, down 0.5 percentage points from fiscal 2025 (11.6%). Over the past ten years it has ranged from 9.11% (fiscal 2015) to 14.5% (fiscal 2022); the current reading is higher than 45% of that period. That is above the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 11.6% | (0.20) |
| FY2024 | 11.8% | (0.32) |
| FY2023 | 12.1% | (2.41) |
| FY2022 | 14.5% | 1.61 |
| FY2021 | 12.9% | 3.62 |
| FY2020 | 9.25% | (2.15) |
| FY2019 | 11.4% | (2.30) |
| FY2018 | 13.7% | 0.96 |
| FY2017 | 12.7% | 2.78 |
| FY2016 | 9.96% | 0.85 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| IDXX IDEXX Laboratories, Inc. compare | 46.0% |
| MTD Mettler-Toledo International, Inc. compare | 35.4% |
| ILMN Illumina, Inc. compare | 16.7% |
| A Agilent Technologies, Inc. | 11.1% |
| DGX Quest Diagnostics Incorporated compare | 8.48% |
| IQV IQVIA Holdings Inc. compare | 6.79% |
| LH Labcorp Holdings Inc. compare | 6.76% |
| WAT Waters Corporation compare | 1.13% |
| NTRA Natera, Inc. compare | −8.35% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on A
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement